Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + basimglurant
- Development stage
- Unknown
- Lead developer
- Noema Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The designation placebo + basimglurant refers to a clinical trial regimen, specifically within the context of the Phase 2B GALENE study (NCT05059327), which utilizes a double-blind, placebo-controlled, crossover design. In this study, participants with uncontrolled seizures associated with Tuberous Sclerosis Complex (TSC) receive both basimglurant and a matching placebo in alternating treatment periods. Basimglurant (also known as NOE-101) is an investigational small molecule that acts as a potent and selective negative allosteric modulator (NAM) of the metabotropic glutamate receptor 5 (mGluR5). By selectively inhibiting mGluR5, basimglurant modulates glutamatergic signaling, which is often overactive in neurological disorders, thereby reducing neuronal excitability and seizure frequency. The drug is being developed by Noema Pharma for orphan neurological conditions, including TSC-related epilepsy, trigeminal neuralgia, and persistent developmental stuttering.
- Other names
- basimglurant
02
Targets
GRM5 (Metabotropic glutamate receptor 5)
Beyond the preview
Go deeper on placebo + basimglurant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + basimglurant.